Rosiglitazone as treatment for clomiphene citrate-resistant polycystic ovary syndrome: Factors associated with clinical response

Journal of Women's Health

Volumn 17, Issue 9, 2008, Pages 1445-1452

  Shokeir, Tarek ^a   El Kannishy, Ghada ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE CITRATE; ROSIGLITAZONE;

ADULT; ARTICLE; BODY MASS; CHEMICAL ANALYSIS; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG RESISTANCE; ECHOGRAPHY; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; INFERTILITY; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; OVULATION; PREGNANCY RATE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

ADULT; ANOVULATION; BODY MASS INDEX; CLOMIPHENE; DRUG RESISTANCE; EGYPT; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; INFERTILITY, FEMALE; LUTEINIZING HORMONE; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TESTOSTERONE; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 56249144808     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2008.0812     Document Type: Article

References (36)

1. The Rotterdam ESHRE/ASRM-Sponsered PCOS Consensus Workshop Group, 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
2. Torre A, Fernandez H. Polycystic ovary syndrome (PCOS). J Gynaecol Obstet Biol Reprod 2007;3:438-439.
3. Setji TL, Brown AJ. Comprehensive clinical management of polycystic ovary syndrome. Minerva Med 2007;36:423-446.
4. Homburg R. Polycystic ovary syndrome. Best Pract Res Clin Obstet Gynecol. September 4, 2007. [Epub ahead of print].
5. Geberhiwot T, Jones AF. Treatment of infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:1999-2001.
6. Guzick DS. Ovulation induction management of PCOS. Clin Obstet Gynecol 2007;50:255-267.
7. Rowe T. Clomiphene citrate: An old favourite lives on. J Obstet Gynaecol Can 2007;29:617-621.
8. Al-Inany H, Johnson N. Drugs for anovulatory infertility in polycystic ovary syndrome. BMJ 2006;332:1461-1462.
9. Stankiewicz M, Norman R. Diagnosis and management of polycystic ovary syndrome: A practical guide. Drugs 2006;66:903-912.
10. Cristello F, Cela V, Artini PG, Genazzani AR. Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecol Endocrinol 2005;21:340-352.
11. Teede HJ, Hutchison SK, Zoungas S. The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol Metab 2007;18:273-279.
12. Teede HJ, Meyer C, Norman RJ. Insulin-sensitisers in the treatment of polycystic ovary syndrome. Expert Opin Pharmacother 2005;6:2419-2427.
13. Nader S. Ovulation induction in women with polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2007;3:438-439.
14. Batherna RK. Therapeutic options in the polycystic ovary syndrome. J Obstet Gynecol 2007;27:123-129.
15. Elkind-Hirsch KE. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome: Impact on metabolic and reproductive abnormalities. Treat Endocrinol 2006;5:171-187.
16. Rouzi AA, Ardawi MS. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 2006;85:428-435
17. Messinis IE. Ovulation induction: A mini review. Hum Reprod 2005;20:2688-2697.
18. Krysiak R, Okopien B, Gdula-Dymek A, Herman ZS. Update on the management of polycystic ovary syndrome. Pharmacol Rep 2006;58:614-625.
19. Kaz A, Nambi SS, Mather K, et al. Quantitative Insulin Sensitivity Check Index: A simple, accurate method for assessing insulin sensitivity in humans. Clin Endocrinol Metab 2000;85:2402-2410.
20. Okon MA, Laird SM, Tuckerman EM, Li TC. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil Steril 1998;69:682-690.
21. Li TC, Spuijbrock MDEH, Tuckerman E, Anstie B, Loxley M, Laird S. Endocrinological and endometrial factors in recurrent miscarriages. Br J Obstet Gynaecol 2000;107:1471-1479.
22. Sample WF, Lippe BM, Gyepes MT. Gray-scale ultrasonography of the normal pelvis. Radiology 1977;125:477-483.
23. Carmina EC, Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovarian syndrome? Fertil Steril 1999;71:319-322.
24. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c 17α activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075-4079.
25. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
26. Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005;90:60-65.
27. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: A randomized placebo-controlled study. Hum Reprod 2006;21:1400-1407.
28. Yilmaz M, Biri A, Karakoç A, et al. The effects of rosiglitazone on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest 2005;28:1003-1008.
29. Pillai A, Bang H, Green C. Metformin and glitazones: Do they really help PCOS patients?. J Fam Pract 2007;56:444-453.
30. Jakubowska J, Bohanowicz-Pawlak A, Milewicz A. The effect of rosiglitazone on plasma adiponectin and resistin levels in obese PCO woman - Preliminary report. Przegl Lek 2007;64:70-73.
31. Ghazeeri G, Kutteh HW, Bryer-Ash M, Hass D, Ke WR. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003;79:562-566.
32. Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Invest 2003;10:99-104.
33. Majuri A, Santaniemi M, Rautio K, et al. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: A randomized placebo-controlled study. Eur J Endocrinol 2007;156:263-269.
34. Seto-Young D, Paliou M, Schlosser J, et al. Direct thiazolidinedione action in the human ovary: Insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 2005;90:6099-6105.
35. Yaris F, Yaris E, Kadioglu M, Ulku C, Kesim M, Kalyoncu NI. Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod Toxicol 2004;18:619-621.
36. Kalyoncu NI, Yaris F, Ulku C, et al. A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod Toxicol 2005;19:563-564.